TY - JOUR
T1 - 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy
T2 - Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
AU - Ommen, Steve R.
AU - Mital, Seema
AU - Burke, Michael A.
AU - Day, Sharlene M.
AU - Deswal, Anita
AU - Elliott, Perry
AU - Evanovich, Lauren L.
AU - Hung, Judy
AU - Joglar, José A.
AU - Kantor, Paul
AU - Kimmelstiel, Carey
AU - Kittleson, Michelle
AU - Link, Mark S.
AU - Maron, Martin S.
AU - Martinez, Matthew W.
AU - Miyake, Christina Y.
AU - Schaff, Hartzell V.
AU - Semsarian, Christopher
AU - Sorajja, Paul
N1 - Publisher Copyright:
© 2020 Lippincott Williams and Wilkins. All rights reserved.
PY - 2020/12/22
Y1 - 2020/12/22
N2 - Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting documentation to encourage their use. Methods A comprehensive literature search was conducted from January 1, 2010, to April 30, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, Agency for Healthcare Research and Quality reports, and other relevant databases. Structure Many recommendations from the earlier hypertrophic cardiomyopathy guidelines have been updated with new evidence or a better understanding of earlier evidence. This summary operationalizes the recommendations from the full guideline and presents a combination of diagnostic work-up, genetic and family screening, risk stratification approaches, lifestyle modifications, surgical and catheter interventions, and medications that constitute components of guideline directed medical therapy. For both guideline-directed medical therapy and other recommended drug treatment regimens, the reader is advised to follow dosing, contraindications and drug-drug interactions based on product insert materials.
AB - Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting documentation to encourage their use. Methods A comprehensive literature search was conducted from January 1, 2010, to April 30, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, Agency for Healthcare Research and Quality reports, and other relevant databases. Structure Many recommendations from the earlier hypertrophic cardiomyopathy guidelines have been updated with new evidence or a better understanding of earlier evidence. This summary operationalizes the recommendations from the full guideline and presents a combination of diagnostic work-up, genetic and family screening, risk stratification approaches, lifestyle modifications, surgical and catheter interventions, and medications that constitute components of guideline directed medical therapy. For both guideline-directed medical therapy and other recommended drug treatment regimens, the reader is advised to follow dosing, contraindications and drug-drug interactions based on product insert materials.
KW - AHA Scientific Statements
KW - atrial fibrillation
KW - cardiovascular magnetic resonance
KW - diastolic dysfunction
KW - echocardiography
KW - exercise stress testing
KW - family screening
KW - genetics
KW - guidelines
KW - hypertrophic cardiomyopathy
KW - implantable cardioverter defibrillator
KW - left ventricular outflow tract obstruction
KW - occupation
KW - physical activity
KW - pregnancy
KW - rhythm monitoring
KW - risk stratification
KW - sarcomeric genes
KW - septal alcohol ablation
KW - septal reduction therapy
KW - shared decision-making
KW - sudden cardiac death
KW - surgical myectomy
KW - systolic dysfunction
KW - ventricular arrhythmias
UR - http://www.scopus.com/inward/record.url?scp=85098112869&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098112869&partnerID=8YFLogxK
U2 - 10.1161/CIR.0000000000000938
DO - 10.1161/CIR.0000000000000938
M3 - Review article
C2 - 33215938
AN - SCOPUS:85098112869
SN - 0009-7322
VL - 142
SP - E533-E557
JO - Circulation
JF - Circulation
IS - 25
ER -